- European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Summary of the document prepared by the Czech Society of Cardiology2014 | Publication without faculty affiliation
- Cost-effectiveness analysis of first-line NOAC prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation2019 | First Faculty of Medicine, Second Faculty of Medicine
- Novel anticoagulants in prevention of cardioembolic stroke in patiens with non-valvular atrial fibrillation2013 | First Faculty of Medicine
- Left atrial platelet aggregability in non-valvular atrial fibrillationPublication without faculty affiliation
- Medication adherence to non-vitamin K antagonist oral anticoagulants at non-valvular atrial fibrillation - the literature review +12017 | Faculty of Pharmacy in Hradec Králové
- Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data2021 | Publication without faculty affiliation
- The results of the RE-LY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular artial fibrillation +12009 | Faculty of Medicine in Hradec Králové
- The results of the RE-LY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular artial fibrillation2009 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BAY59-7939/11630Publication without faculty affiliation
- Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Summary of the document prepared by the Czech Society of Cardiology2016 | Faculty of Medicine in Hradec Králové
- Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke2019 | Third Faculty of Medicine
- Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry2017 | Publication without faculty affiliation
- Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA(2)DS(2)-VASc score of 1 A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke2019 | Central Library of Charles University
- Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatrantreated patients: a series of 11 cases2017 | Faculty of Medicine in Hradec Králové
- Edoxaban - new FXa inhibitor2017 | Publication without faculty affiliation
- Edoxaban - medication profile2013 | Publication without faculty affiliation
- Apixaban has been available for the treatment of venous thromboembolic disease for more than two years +12017 | First Faculty of Medicine, Third Faculty of Medicine
- Dabigatran in the prevention of stroke in patients with atrial fibrilation2011 | First Faculty of Medicine, Third Faculty of Medicine
- Treatment of emergencies associated with bleeding risk in patients taking new oral anticoagulants - options concerning termination of their effect2016 | First Faculty of Medicine, Third Faculty of Medicine
- Anticoagulant Therapy in the Prevention and Treatment of Ischemic Stroke2010 | First Faculty of Medicine
- Prevention of cardioembolic stroke2012 | First Faculty of Medicine
- Wasn't there any other way? First experiences with idarucizumab in Pilsen - case reports2017 | Publication without faculty affiliation